| pubmed-article:1706741 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1706741 | lifeskim:mentions | umls-concept:C0524909 | lld:lifeskim |
| pubmed-article:1706741 | lifeskim:mentions | umls-concept:C0279030 | lld:lifeskim |
| pubmed-article:1706741 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:1706741 | pubmed:dateCreated | 1991-4-30 | lld:pubmed |
| pubmed-article:1706741 | pubmed:abstractText | A study is currently underway to investigate the efficacy of interferon therapy in patients with prolonged (greater than or equal to 10 weeks but less than 6 months) hepatitis B infection. To date, a total of 15 patients have been enrolled in the study and randomly assigned to receive either placebo for 24 weeks (n = 8) or interferon 5 million units subcutaneously 3 times a week for 24 weeks (n = 7), with follow up for 1 year. Thirteen patients have completed the follow-up period: seven patients in the placebo group and six in the treated group. Five of the six treated patients completely eradicated the infection during interferon therapy, with clearance of hepatitis B e and surface antigens, and seroconversion to antibody positivity in each case. Two of the eight placebo patients seroconverted during the placebo period. Clearance of hepatitis B e antigen was associated with a sudden rise in serum transaminase levels and an exacerbation of hepatitis, a phenomenon that has also been reported in chronic hepatitis B patients who have responded well to interferon therapy. Therapy was well tolerated in all cases. Our results suggest that interferon treatment of patients with prolonged hepatitis B infection may prevent progression to chronicity. If confirmed by further study, they should trigger more vigilant screening for patients with raised serum transaminase levels and viral markers of hepatitis B infection. | lld:pubmed |
| pubmed-article:1706741 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1706741 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1706741 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1706741 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1706741 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1706741 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1706741 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1706741 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1706741 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1706741 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1706741 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1706741 | pubmed:issn | 0168-8278 | lld:pubmed |
| pubmed-article:1706741 | pubmed:author | pubmed-author:TrépoCC | lld:pubmed |
| pubmed-article:1706741 | pubmed:author | pubmed-author:PetitM AMA | lld:pubmed |
| pubmed-article:1706741 | pubmed:author | pubmed-author:ChevallierPP | lld:pubmed |
| pubmed-article:1706741 | pubmed:author | pubmed-author:SepetjanMM | lld:pubmed |
| pubmed-article:1706741 | pubmed:author | pubmed-author:ChossegrosPP | lld:pubmed |
| pubmed-article:1706741 | pubmed:author | pubmed-author:ZoulimFF | lld:pubmed |
| pubmed-article:1706741 | pubmed:author | pubmed-author:CheminII | lld:pubmed |
| pubmed-article:1706741 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1706741 | pubmed:volume | 11 Suppl 1 | lld:pubmed |
| pubmed-article:1706741 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1706741 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1706741 | pubmed:pagination | S95-9 | lld:pubmed |
| pubmed-article:1706741 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:meshHeading | pubmed-meshheading:1706741-... | lld:pubmed |
| pubmed-article:1706741 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1706741 | pubmed:articleTitle | Possible prevention of chronic hepatitis B by early interferon therapy. | lld:pubmed |
| pubmed-article:1706741 | pubmed:affiliation | Service d'Hépatogastroentérologie, Hôtel Dieu, France. | lld:pubmed |
| pubmed-article:1706741 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1706741 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1706741 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1706741 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1706741 | lld:pubmed |
